RICHMOND, Va., March 28, 2003 (PRIMEZONE) -- Investors interested in biotech and phase III drug companies and their investment value can gather insights as Insmed, Inc. (Nasdaq:INSM) presents at Informed Investors' forum on Thursday, April 3.
This free online Forum gives investors the opportunity to hear directly from biotech and phase III drug company executives. The presentation will be accessible live at www.informedinvestors.com beginning at 9:00 a.m. EST. As part of the forum, investors are invited to email questions to the executives. The forum will also be archived and available afterwards on www.informedinvestors.com and www.vcall.com.
Insmed, Inc. is a biopharmaceutical company engaged in the development of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. The Company is entering a pivotal Phase III trial this spring in growth hormone insensitivity syndrome (GHIS) with its lead drug candidate rhIGF-I/IGFBP-3. Insmed expects to conduct a six-month interim analysis in this trial in early 2004, and upon positive analysis, the Company intends to file for marketing approval. Please contact Insmed's investor relations representative, Baxter Phillips at 804.565.3041 or at bphillips@insmed.com for more information about the drug development program at Insmed.
Geoffrey Allan, Ph.D., Chief Executive Officer, President and Chairman of the Board of Insmed, Inc., is a seasoned pharmaceutical industry executive with more than 20 years experience in drug research and development at both early-stage and mature companies. Dr. Allan joined Insmed Pharmaceuticals in 1994 as President and Chief Technical Officer. Since that time, he took the company from private to public status, built strong scientific management and clinical organization and raised more than $120 million. Dr. Allan holds several patents and has been published extensively in cardiovascular research and therapeutic drug developments. He received his Ph.D. in pharmacology from Cornell University Medical College.
Informed Investors is the leading producer of online and offline industry-specific investment conferences for investors and a member of the WILink suite of PrecisionIR(tm) services serving publicly traded companies and self-reliant investors. Companies wanting to participate in the forum should contact Tracy Jones at tjones@wilink.com.
About WILink
Since 1992, WILink plc (www.wilink.com) has been a leading provider of global investor relations and investment information services that attract and retain investors for public companies and mutual funds. WILink's PrecisionIR(tm) (www.precisionir.com) and PrecisionFM(tm) custom investor-marketing programs enable publicly traded companies and mutual funds to deliver tailored and compelling communications to a precisely targeted audience of investors. This year WILink will make more than 8 million investor introductions for over 3,750 corporate clients through PrecisionIR(tm) and PrecisionFM(tm) programs, which include the Annual Reports Service, the Fund Info Service, Informed Investors Forums (www.informedinvestors.com), Vcall(r) webcasting (www.vcall.com), InstitutionalReach(tm) and PeerEvents. WILink's partnerships with over 240 leading financial channels in 14 countries including The Wall Street Journal, Financial Times, Barron's and Yahoo! Finance ensure clients targeted visibility within the investment community. WILink, Inc. a wholly owned subsidiary of WILink plc (WLK: LSE) began operations in Richmond, Va. in 1993.